SES
9.9.2019 08:57:15 CEST | Business Wire | Press release
SES announced today it is developing a broadcast-grade managed cloud service offering on Microsoft Azure as a result of an expanded collaboration with Microsoft. Benefitting from Azure’s extensive cloud and AI capabilities, and its own expertise in providing managed services for leading broadcasters and media companies worldwide, SES is transforming media service delivery via the cloud.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190908005052/en/
This service will provide end-to-end, service-level agreement (SLA)-based media delivery services on Azure, giving broadcasters and media companies the flexibility and scalability that are essential in today’s rapidly changing media environment. Bringing the most relevant content to the cloud and providing innovative services covering the entire video value chain – ingest, playout, and delivery – will enable media companies to scale and address the consumer’s growing demand for a premium viewing experience on every screen.
SES leads the industry with its worldwide reach of over 355 million TV households (or 1 billion people) and distributes over 8,200 channels via satellite. With SES’s recent unification of its wholly owned video services subsidiary, MX1, with its SES Video business unit, SES now manages over 525 channels and delivers more than 8,400 hours of online video streaming, including over 620 hours of premium sports and live events per day. Going to market with a unified solution for video infrastructure and services means that SES will accelerate the rollout of hybrid linear and non-linear content delivery services and solutions with unprecedented global reach.
At IBC2019, SES will demonstrate two initial use cases for its new service with Azure. Visitors to the SES stand (1.B51) will be able to witness first-hand:
- Fully managed playout services on Azure, including master playout and localised playout including ad detection and replacement
- The advantages of efficient, high-quality multichannel live IP encoding managed 24/7 by SES on Azure
“Our collaboration with Microsoft Azure will enable us to take our portfolio of media services and distribution solutions to the next level,” said Ferdinand Kayser, CEO of SES Video. “Our cloud-enabled media service will be unique to the industry and will offer scalability and flexibility, along with increased broadcast quality of service, thanks to the latest AI and machine learning capabilities.”
Tad Brockway, Corporate Vice President, Azure Storage, Media, & Edge, Microsoft Corp. “Broadcasters and media companies need solutions to deliver high-quality video services globally with maximum flexibility, scalability, and reliability. We look forward to working with SES to deliver these new solutions on Azure.”
SES also announced today an expanded relationship with Microsoft that enables connectivity between SES’s multi-orbit satellite systems and Azure ExpressRoute . This initiative builds on the companies’ broader strategic collaboration and their shared common vision to reach everyone with intelligent cloud, media and network solutions.
The SES stand at IBC 2019 is located at stand 1.B51. More details of SES presence at the event available here .
Follow us on:
Social Media
Blog
Media Library
About SES
SES is the world’s leading satellite operator with over 70 satellites in two different orbits, Geostationary Orbit (GEO) and Medium Earth Orbit (MEO). It provides a diverse range of customers with global video distribution and data connectivity services through two business units: SES Video and SES Networks. SES Video reaches over 355 million TV homes, through Direct-to-Home (DTH) platforms and cable, terrestrial, and IPTV networks globally. SES Video delivers a full suite of innovative end-to-end value-added services for both linear and digital distribution, and includes the ASTRA satellite system, which has the largest DTH television reach in Europe. SES Networks provides global managed data services, connecting people in a variety of sectors including telecommunications, maritime, aeronautical, and energy, as well as governments and institutions across the world. The SES Networks portfolio includes GovSat, a 50/50 public-private partnership between SES and the Luxembourg government, and O3b, the only non-geostationary system delivering fibre-like broadband services today. Further information is available at: www.ses.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190908005052/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom